DRUG DEVELOPMENT PIPELINE

Back to the Drug Development Pipeline

SPX-101

Phase Two

Phase Two

Therapeutic Approach

Mucociliary Clearance

SPX-101 is a compound designed to block the function of the sodium (Na+) channel found in the lungs. These channels move sodium and water away from the airway surface. Blocking these channels may help maintain fluid within the airways to improve mucus clearance. 

Status

A phase two study to test the safety and effectiveness of SPX-101 in people with CF is planned. 

Sponsor

This program is sponsored by Spyryx Biosciences and partially funded by Cystic Fibrosis Foundation Therapeutics (CFFT). 

Contact us about SPX-101 >